Literature DB >> 24990904

Immunogenicity of the trivalent inactivated influenza vaccine in young children less than 4 years of age, with a focus on age and baseline antibodies.

Ayumi Mugitani1, Kazuya Ito2, Shin Irie3, Takashi Eto4, Motoki Ishibashi4, Satoko Ohfuji5, Wakaba Fukushima5, Akiko Maeda5, Yoshio Hirota6.   

Abstract

In this study, we assessed the effects of the prevaccination titer and age on the immunogenicity of a low dose of influenza vaccine in children less than 4 years of age. A total of 259 children received two vaccine doses (0.1 ml for 0-year-olds and 0.2 ml for children 1 year of age or older) 4 weeks apart during the 2005/2006 season. The hemagglutination inhibition antibody titers were measured before vaccination and 4 weeks after the first and second doses. The geometric mean titer, mean fold rise, seroresponse proportion (≥4-fold rise in titer), and seroprotection proportion (titer ≥1:40) were calculated for the prevaccination titer and age categories. A multivariate logistic regression analysis was performed using the seroresponse and seroprotection proportions as dependent variables and the prevaccination titer and age as explanatory variables. As for the seroresponse against the H1 antigen after the first dose, the adjusted odds ratios of the prevaccination titers (versus <1:10) were 2.2 (95% confidence interval, 0.8 to 5.8) at 1:10 to 1:20 and 0.14 (0.04 to 0.49) at ≥1:40. The corresponding figures for ages were 0.03 (0.01 to 0.07) for the 0-year-olds and 0.17 (0.08 to 0.34) for the 1-year-olds compared with the 2- to 3-year-olds (Ptrend < 0.001). Similar results were also obtained for the H3 and B strains. Significantly elevated odds ratios for seroprotection were observed with greater prevaccination titers and older ages for all strains. The prevaccination titer and age were independently associated with the antibody response in young children. The immune response was weaker in the younger children and those without preexisting immunity.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24990904      PMCID: PMC4178574          DOI: 10.1128/CVI.00200-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  27 in total

1.  Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.

Authors:  Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

2.  Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally?

Authors:  Emmanuel B Walter; Shilpa Rajagopal; Yuwei Zhu; Kathleen M Neuzil; Mary P Fairchok; Janet A Englund
Journal:  Vaccine       Date:  2010-05-04       Impact factor: 3.641

3.  Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.

Authors:  James C King; Manon M Cox; Keith Reisinger; James Hedrick; Irene Graham; Peter Patriarca
Journal:  Vaccine       Date:  2009-08-27       Impact factor: 3.641

4.  Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.

Authors:  Giovanni Della Cioppa; Timo Vesikari; Etienne Sokal; Kelly Lindert; Uwe Nicolay
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

5.  Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses.

Authors:  Debra P Ritzwoller; Carolyn Buxton Bridges; Susan Shetterly; Kristi Yamasaki; Margarette Kolczak; Eric K France
Journal:  Pediatrics       Date:  2005-07       Impact factor: 7.124

6.  Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months.

Authors:  Danuta M Skowronski; Travis S Hottes; Mei Chong; Gaston De Serres; David W Scheifele; Brian J Ward; Scott A Halperin; Naveed Z Janjua; Tracy Chan; Suzana Sabaiduc; Martin Petric
Journal:  Pediatrics       Date:  2011-07-18       Impact factor: 7.124

7.  A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.

Authors:  Janet A Englund; Emmanuel B Walter; Mary P Fairchok; Arnold S Monto; Kathleen M Neuzil
Journal:  Pediatrics       Date:  2005-04       Impact factor: 7.124

8.  Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2013-09-20

Review 9.  Quantitative review of antibody response to inactivated seasonal influenza vaccines.

Authors:  Jessica C Seidman; Stephanie A Richard; Cécile Viboud; Mark A Miller
Journal:  Influenza Other Respir Viruses       Date:  2011-06-13       Impact factor: 4.380

10.  Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children.

Authors:  Terry Nolan; Peter C Richmond; Jodie McVernon; Maryanne V Skeljo; Gunter F Hartel; Jillian Bennet; Russell L Basser
Journal:  Influenza Other Respir Viruses       Date:  2009-11       Impact factor: 4.380

View more
  8 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  Prior vaccinations improve immunogenicity of inactivated influenza vaccine in young children aged 6 months to 3 years: A cohort study.

Authors:  Kazuya Ito; Ayumi Mugitani; Shin Irie; Motoki Ishibashi; Yoshio Takasaki; Shizuo Shindo; Takashi Yokoyama; Yuji Yamashita; Keigo Shibao; Hideki Koyanagi; Wakaba Fukushima; Satoko Ohfuji; Akiko Maeda; Tetsuo Kase; Yoshio Hirota
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

3.  Characterising antibody kinetics from multiple influenza infection and vaccination events in ferrets.

Authors:  James A Hay; Karen Laurie; Michael White; Steven Riley
Journal:  PLoS Comput Biol       Date:  2019-08-19       Impact factor: 4.475

4.  Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months.

Authors:  Jee Hyun Lee; Hye Kyung Cho; Ki Hwan Kim; Jina Lee; Yae Jean Kim; Byung Wook Eun; Nam Hee Kim; Dong Ho Kim; Dae Sun Jo; Hwang Min Kim; Yun Kyung Kim
Journal:  J Korean Med Sci       Date:  2019-12-02       Impact factor: 2.153

5.  Mapping Host-Related Correlates of Influenza Vaccine-Induced Immune Response: An Umbrella Review of the Available Systematic Reviews and Meta-Analyses.

Authors:  Alexander Domnich; Ilaria Manini; Giovanna Elisa Calabrò; Chiara de Waure; Emanuele Montomoli
Journal:  Vaccines (Basel)       Date:  2019-12-13

6.  Systematic characterization of human response to H1N1 influenza vaccination through the construction and integration of personalized transcriptome response profiles.

Authors:  Carlo De Intinis; Margherita Bodini; Denise Maffione; Laurane De Mot; Margherita Coccia; Duccio Medini; Emilio Siena
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.379

7.  The Epidemiological Pattern and Co-infection of Influenza A and B by Surveillance Network From 2009 to 2014 in Anhui Province, China.

Authors:  Jun He; Sai Hou; Yue Chen; Jun-Ling Yu; Qing-Qing Chen; Lan He; Jiang Liu; Lei Gong; Xin-Er Huang; Jia-Bing Wu; Hai-Feng Pan; Rong-Bao Gao
Journal:  Front Public Health       Date:  2022-02-24

8.  Efficacy of trivalent influenza vaccine against laboratory-confirmed influenza among young children in a randomized trial in Bangladesh.

Authors:  Melissa A Rolfes; Doli Goswami; Amina Tahia Sharmeen; Sultana Yeasmin; Nasrin Parvin; Kamrun Nahar; Mustafizur Rahman; Marion Barends; Dilruba Ahmed; Mohammed Ziaur Rahman; Joseph Bresee; Stephen Luby; Lawrence H Moulton; Mathuram Santosham; Alicia M Fry; W Abdullah Brooks
Journal:  Vaccine       Date:  2017-10-31       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.